TRAPPC13

Across TCGA pan-cancer cohorts, TRAPPC13 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRAPPC13 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRAPPC13 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TRAPPC13 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where TRAPPC13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.328	0.846	.011	7	view →
UCEC	DFS	Median	All	0.953	0.853	.020	6	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →
GBM	OS	Quartile	All	0.975	0.660	.012	2	view →
HNSC	OS	Tertile	II,III,IV	1.000	0.937	.040	1	view →
CCRCC	OS	Tertile	III,IV	0.833	0.524	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRAPPC13–PDAC (OS)

Open the PDAC breakdown →